Based on enzyme-linked immunosorbent assays (ELISA), a recent study profiled the plasma proteomics of NSCLC patients and identified CXCL8 and CXCL10 as biomarker for inferior response to ICI [13]. The gene discussed is CXCL10; the disease is non-small cell lung carcinoma.